-
Phase 1
-
-
18-55Age Range
-
1Locations
-
Recruiting
Menu
Thank you for submitting your question. You will get a reply within two business days to the email you provided. Thank you.
Recruiting
A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants
The purpose of this study is to evaluate the excretion pathway of orally administered [14C]-BMS-986196 and to assess the safety and tolerability of orally administered BMS-986196.
Inclusion Criteria: - Healthy male participants without clinically significant deviation from normal in medical history, electrocardiogram (ECG), clinical laboratory determinations, and Day -1 physical examination. - Body mass index of 18.0 to 35.0 kilograms/meter square (kg/m^2), inclusive, and total body weight ≥ 50 kg Exclusion Criteria: - Any significant acute or chronic medical illness as determined by the investigator. - A history of clinically significant hepatic or pancreatic disease. - Current or recent (within 3 months prior to study treatment administration) gastrointestinal disease that could impact upon the absorption, distribution, metabolism, or excretion of study treatment as determined by the investigator. Note: Other protocol-defined inclusion/exclusion criteria apply.
Study Arms
Experimental: [14C]-BMS-986196